McLaughlin Matthew T E 4
4 · Oxford Immunotec Global PLC · Filed Mar 12, 2021
Insider Transaction Report
Form 4
McLaughlin Matthew T E
Chief Financial Officer
Transactions
- Disposition to Issuer
Ordinary Shares
2021-03-08$22.00/sh−61,407$1,350,954→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-08$6.03/sh−25,044$151,015→ 0 totalExercise: $15.97Exp: 2029-04-08→ Ordinary Shares (25,044 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-08$9.81/sh−34,795$341,339→ 0 totalExercise: $12.19Exp: 2030-03-11→ Ordinary Shares (34,795 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-08$6.03/sh−32,064$193,346→ 0 totalExercise: $15.97Exp: 2029-04-08→ Ordinary Shares (32,064 underlying)
Footnotes (3)
- [F1]Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
- [F2]In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
- [F3]Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.